CBA第24届年会在广州主办(6月10日)

Posted By on May 29, 2019

美国华人生物医药科技协会

CBA供稿 许鹏 撰稿

美国华人生物医药科技协会(CBA)第24届年会

注册二维码

美国华人生物医药科技协会(CBA)年会是一个领先的生命科学论坛,每年都吸引了来自中美最有影响力的组织,科学研发专家,监管机构,投资者和企业高管。 经过近一年的精心策划多方联络,美国华人生物医药科技协会第24届2019年会将与中国生物产业大会BioChina ((http://www.bio-industry.org.cn/index.html)) 共同主办,6月10日在中国广州白云国际中心隆重开幕.

CBA年会是了解当前生物科技医药发展动态,会见当地生物企业和研究机构顶尖人物,开展业务拓展的极佳机会。本次年会的主题是“引领生物医药尖端技术,推进产业化和全球合作”。来自全球科研界、工业界、医疗界的杰出代表将展示当前生物研究前沿,结合尖端技术与技术产业化为宗旨,共同推动中美乃至全球生命医学领域的创新发展。

此次年会,众星闪耀 – 其中包括诺贝尔获得者Aaron Ciechanover博士, 微软首席医学官Simon Kos博士, 哈佛大学医学院Raju Kucherlapati院士, , 前MD安德森癌症研究所主任Lynda Chin院士,国家肝癌科学中心主任, 国家自然科学基金委员会医学科学部主任王红阳院士,加卅大学旧金山分校Charles Craik院士, 中国科学院上海药物研究所陈凯先院士, 华中科大樊明武院士,华润生命科学产业发展有限公司董事长颜建国 博士等学界产业界大咖, 红杉资本中国基金董事总经理杨云霞, 广州民营投资股份有限公司 首席运营官钟育 彬等众多资本大佬。

不可错过的机会加上CBA真诚地邀请,期待与您一起见证生物生命医学领域的一大盛事!扫描注册二维码:

知名嘉宾:

1. Aaron Ciechanover博士, 诺奖获得者, 美、中科学院院士

Aaron Ciechanover博士, 诺奖获得者, 美、中科学院院士

Aaron Ciechanover于1947年出生于以色列。他目前是以色列海法以色列理工学院医学院的杰出大学教授。他获得了耶路撒冷希伯来大学的硕士学位 (1971)和M.D.(1973)以及Technion博士学位(1982)。在那里,作为Hershko博士的研究生,与费城的罗斯博士合作,他们发现用泛素标记蛋白质底物,将其靶向蛋白酶体降解。多年来,泛素介导的蛋白水解在许多细胞过程中起主要作用,并且系统中的畸变是许多疾病的致病机制的基础,其中包括某些恶性肿瘤和神经退行性疾病。因此,该系统已成为药物开发的重要平台。他获得的奖项包括2000年Albert Lasker奖,2003年以色列奖和2004年诺贝尔奖(化学;与Hershko和Rose博士分享)。在学术界,他是以色列国家科学院和人文科学院,美国国家科学院(NAS)和医学院(NAM)(外国会员)和中国科学院(CAS;外籍会员)。

Aaron Ciechanover was born in Israel in 1947. He is currently a distinguished University Professor in the Faculty of Medicine at the Technion-Israel Institute of Technology in Haifa, Israel. He received his M.Sc. (1971) and M.D. (1973) from the Hebrew University in Jerusalem, and his Ph.D. from the Technion (1982). There, as a graduate student with Dr. Hershko and in collaboration with Dr. Rose from Philadelphia, they discovered that tagging of protein substrates with ubiquitin, target them for proteasomal degradation. Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Consequently, the system has become an important platform for drug development. Among the prizes he received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose). Among the learnt societies, he is a member of the Israeli National Academy of Sciences and Humanities, the National Academies of Sciences (NAS) and Medicine (NAM) of the USA )(Foreign Member), and the Chinese Academy of Sciences (CAS; Foreign Member).

2. Simon Kos搏士, 微软首席医学官

Simon Kos搏士, 微软首席医学官

Simon Kos博士是微软全球健康部门的首席医疗官。 Kos于2010年加入微软,从事医疗保健和健康IT行业超过17年的洞察力和经验。作为微软全球健康团队的医生,他负责临床战略和行业参与。他提高了对微软品牌,技术和合作伙伴社区的认识,并努力寻找微软产品的临床相关。

Dr. Simon Kos is the Chief Medical Officer, Worldwide Health, Microsoft. Kos joined Microsoft in 2010 bringing insight and experience from over 17 years working in the healthcare and Health IT industries. As the doctor on Microsoft’s Worldwide Health team, he is responsible for clinical strategy and industry engagement. He raises awareness of the Microsoft brand, technologies and partner community, and works to find clinical relevance for Microsoft products.

3. Raju Kucherlapati院士, 哈佛大学医学院

Raju Kucherlapati院士, 哈佛大学医学院

美国科学院院士,哈佛大学医学院教授,是哈佛大学医学院遗传学和基因组学医疗保健研究中心(HPCGG)首位科学主管。Kucherlapati博士的研究领域主要包括基因定位和同源重组,人类基因组图谱,以及描绘人类12号染色体带有特殊位点的人类基因组的自然图谱。Kucherlapati博士是人类基因组描绘和测序联盟的成员,他成功的开发了基因修饰技术来修饰哺乳动物细胞的基因和多种人类疾病相关基因。在过去的几年里,他一直是癌症和肿瘤基因图谱(TCGA)计划的一部分同时也是基因组研究中心的PI。Raju Kucherlapati博士是美国国立卫生研究院几个审查委员会主席及成员,是美国国家人类基因组研究所有关人类基因组研究的国家咨询委员会成员,同时也是美国国家癌症研究所人源肿瘤应用于小鼠模型的指导委员会主席。Kucherlapati博士是新英格兰医学杂志的编委,也是该杂志基因组的主编。他还是美国科学发展协会及美国国家医学科学院的成员。

Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School. He was the founding Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics. Dr. Kucherlapati obtained his Ph.D. from the University of Illinois, was a post-doctoral fellow at Yale University and was a faculty member at Princeton University and the University of Illinois Medical School in Chicago. Prior to his Harvard appointment, Dr. Kucherlapati was the University Professor and Chair of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. Dr. Kucherlapati was involved in developing methods for gene targeting in mammalian cells, was a part of the Human Genome Project and The Cancer Genome Atlas Project of the National Institutes of Health. His lab cloned many human disease genes. He was an Editor-in-Chief of the journal Genomics and served on the editorial board of the New England Journal of Medicine. He is a member of the National Academy of Medicine and a Fellow of the American Association for the Advancement of Science. Dr. Kucherlapati also served as a member of the Presidential Commission for the Study of Bioethical Issues during the Obama administration.

4. Lynda Chin院士,Apricity Health LLC. 前MD安德森癌症研究所主任

Lynda Chin院士,Apricity Health LLC. 前MD安德森癌症研究所主任

作为国家医学院的当选成员,Chin博士是着名的癌症基因组学家,也是应用技术,AI / ML和医学大数据的领导者。她曾在Dana Farber癌症研究所和哈佛医学院进行癌症基因组学和癌症生物学研究,曾在癌症基因组图谱(TCGA)的执行小组委员会任职,并在Broad研究所共同领导Firehose的开发。作为MD安德森癌症中心基因组医学系的创始主席,她发起了利用技术,数据和分析开发跨领域平台功能的计划,包括APOLLO平台,系统化面向患者的研究工作流程,转换研究加速器( TRA)整合精准医学的纵向临床和研究数据,以及肿瘤学专家顾问将AI / ML应用于循证护理的民主化。后来,作为德克萨斯大学系统的首席创新官,Chin博士创建了健康转型研究所,以探索将数据和数字技术整合到护理服务中的策略,特别是对于服务不足的人。她开发了REDI(真实世界教育,早期检测和干预),一个21世纪版本的PCMH(以患者为中心的医疗之家),并在德克萨斯州南部的一个最贫困的社区(项目DOC)实施,以展示技术 – 为弱势群体提供医疗服务。最近,Chin博士创立了Apricity Health,开发综合的专家级数字疗法,通过将世界一流的专业知识运用于肿瘤科医生的手中,从而提高癌症治疗和患者生活质量的实际效果。免疫治疗。

An elected member of the National Academy of Medicine, Dr. Chin is a renowned cancer genomic scientist and a leader in application of technologies, AI/ML and big data in medicine. She conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute. As founding chair of the Department of Genomic Medicine at MD Anderson Cancer Center, she launched initiatives to develop cross-cutting platforom capabilities with technologies, data and analytics, including the APOLLO platform to systematize workflows for patient-oriented research, the Translational Research Accelerator (TRA) to integrate longitudinal clinical and research data for precision medicine, and the Oncology Expert Advisor to apply AI/ML for democratization of evidence-based care. Later, as Chief Innovation Officer of the University of Texas System, Dr. Chin created the Institute for Health Transformation to explore strategies for integrating data and digital technologies in care delivery, especially for the underserved. She developed the REDI (Real-world Education, early Detection and Intervention), a 21st century version of PCMH (Patient-Centered Medical Home), and implemented it in one of the poorest communities in South Texas (Project DOC) to demonstrate technology-enabled care delivery for a vulnerable population. More recently, Dr. Chin founded Apricity Health to develop integrated expert-powered digital therapeutics to improve the real-world effectiveness of cancer treatments and quality-of-life of patients by putting world-class expertise in the hands of practicing oncologists, starting with immunotherapy.

5. 王红阳院士,国家肝癌科学中心主任, 国家自然科学基金委员会医学科学部主任

王红阳院士,国家肝癌科学中心主任, 国家自然科学基金委员会医学科学部主任

王红阳教授,女,主任医师,博士生导师,肿瘤学、分子生物学专家,中国工程院院士,发展中国家科学院院士,国家杰出青年基金获得者。现任国家肝癌科学中心主任、国际合作生物信号转导研究中心主任。兼任中国抗癌协会副理事长,中国医师协会精准医学专业委员会主任委员,上海市医学会副会长。

长期从事肿瘤的基础与临床研究,对肿瘤的炎-癌转化、信号网络调控和肝癌诊断试剂研发等有重要建树。在国际有影响的主流期刊发表SCI论文200余篇;近五年申报发明专利28项,已获授权12项(国际专利2项),主持研发的Glypican-3肝癌诊断试剂已获国家食品药品监督管理总局(CFDA)批复临床应用(是我国第一个具有完全自主产权获批的肝癌诊断试剂盒)。先后主持国家和省部级重大、重点科技攻关项目十余项。 以第一完成人获首届国家科学技术进步奖创新团队奖、国家自然科学二等奖、上海市自然科学一等奖、上海医学科技一等奖等9项,获全国三八红旗手标兵、总后勤部“科技金星”、上海市“十大科技精英”和上海市“优秀学科带头人”等称号,获韩国爱茉莉太平洋杰出女科学家奖,巾帼创新奖和首届“五洲女医师奖” 等。曾先后荣立一等功、二等功和三等功。

Dr. Hongyang Wang is the director and professor of the center for signal transduction in the Institute of Oriental Department of hepatobiliary surgery in Shanghai. She engaged in basic and clinical research in cancer therapy and had built on the research of signal transduction of tumor, especially the signal transduction and early diagnostic markers of liver cancer. She has also undertaken many important topics such as “973”, “863” and National Natural Science Foundation. She has enjoyed a high reputation in medical field both in country and overseas.

6. Charles Craik院士, 加卅大学旧金山分校

Charles Craik院士, 加卅大学旧金山分校

“Global Analysis of Proteolysis for Discovery and Benefit to Patient Health”

全面分析蛋白酶解方法在科研和患者健康的应用

Charles S. Craik is a Professor at UCSF and is also the founder and co-director of the Chemistry and Chemical Biology Graduate Program. He joined the faculty in 1985 where his research interests focus on defining the roles and the mechanisms of enzymes and other challenging proteins in complex biological processes and on developing technologies to facilitate these studies. Current research in the Craik lab is on the chemical biology of post translational modifying enzymes, receptors and membrane transporters. A particular emphasis of his work is on identifying the roles and regulating the activity of proteases and degradative enzyme complexes associated with infectious diseases, neurodegenerative diseases and cancer. He is also interested in developing novel methods to biophysically characterize challenging proteins as well as their complexes. These studies coupled with his global substrate profiling, antibody engineering and noninvasive imaging efforts are providing a better understanding of both the chemical make-up and the biological importance of these critical proteins to aid in the rapid detection, monitoring and control of disease. Craik a founder of Catalyst Biosciences, a Fellow of the American Association for the Advancement of Science (AAAS), the National Academy of Inventors (NAI), the American Academy of Arts and Sciences and the 2016 awardee of the Emil Kaiser Award by the Protein Society.

Charles S. Craik是加州大学旧金山分校的教授,也是化学和化学生物学研究生课程的创始人和联合主任。他于1985年加入该学院,他的研究兴趣集中在确定酶和其他具有挑战性的蛋白质在复杂生物过程中的作用和机制,以及开发促进这些研究的技术。目前Craik实验室的研究是关于翻译后修饰酶,受体和膜转运蛋白的化学生物学。他的工作的一个特别重点是确定与传染病,神经退行性疾病和癌症相关的蛋白酶和降解酶复合物的作用和调节活性。他还对开发用于生物物理表征具有挑战性的蛋白质及其复合物的新方法感兴趣。这些研究结合他的全球底物分析,抗体工程和非侵入性成像工作,可以更好地了解这些关键蛋白质的化学组成和生物学重要性,以帮助快速检测,监测和控制疾病。 Craik是Catalyst Biosciences的创始人,美国科学促进会(AAAS),美国国家发明学会(NAI),美国艺术与科学学院院士以及2016年蛋白质协会的Emil Kaiser奖获得者。

7. 华润生命科学产业发展有限公司董事长 颜建国

华润生命科学产业发展有限公司董事长 颜建国

“Innovation Practice of Whole Life Science Industry Chain”

生命科学产业全周期创新实践

Mr. Yan Jianguo is Senior Deputy Chief Strategy Officer of Strategy Management Department, China Resources Group. Mr. Yan holds an EMBA degree from the China Europe International Business School. Mr. Yan’s previous positions included Deputy General Manager of Beijing Division of China Resources Land, General Manager of China Everbright Real Estate, and Chairman & General Manager of Everbright Eco-technology. Mr.Yan has rich working experience in energy, environmental protection, real estate, tourism, healthcare and other industries. Mr. Yan will deliver a keynote presentation of Innovation Practice of Whole Life Science Industry Chain.

颜建国先生担任华润集团战略管理部高级副总监。颜先生持有中欧国际工商学院高级管理人员工商管理硕士学位,曾在华润置地(北京)股份有限公司、中国光大集团光大置业有限公司、光大生态技术有限公司等企业任职,熟悉能源、环保、房地产、旅游、大健康、大数据等多个行业,善于多产业跨界联动。颜先生的演讲题目是生命科学产业全周期创新实践。

8. 陈凯先博士,中国科学院院士, 中国科学院上海药物研究所

陈凯先博士,中国科学院院士, 中国科学院上海药物研究所

“Frontier of Biopharmaceutical Technologies and Development Trend in China”

生物医药科技前沿动向和我国发展态势

Dr. Kaixian Chen has committed himself to research in the areas of organic chemistry, medicinal chemistry and drug design for many years. Through theoretical calculation and molecular modeling, his group has developed and improved many methods and techniques for drug design, studied in depth structure-function relationships of many biological macromolecules, structure-activity relationships as well as mechanism of action of a significant number of biologically active small molecules. Focusing on a series of important drug targets, his team has conducted high throughput virtual screenings, lead discovery researches, prediction and design of biological active small molecules. Through these studies, Dr. Chen has promoted the interdisciplinary exchanges and integrations among medicinal chemistry, life sciences, computer science and informatics, achieving a contribution towards innovative drug research in China. He will deliver a keynote presentation on the Frontier of Biopharmaceutical Technologies and Development Trend in China.

陈凯先院士主要从事药物化学和创新药物研究。他长期致力于药物构效关系和生物活性小分子化合物结构预测的研究,并与其研究团队一起提出和改进了多种计算机辅助药物设计的方法和技术,包括分子疏水作用力场和药物构像研究的方法、药效基团搜寻方法、利用计算机构建具有结构多样性的分子库和模拟筛选的方法等,并应用于多种药物与生物大分子相互作用的分子模拟和理论研究。他积极开展基于药物与受体三维结构的药物设计研究,其中一些药物设计研究工作得到验证,发现了多种有望发展成新药的化合物。这些创新的研究工作促进了有机化学、生命科学和计算机科学的跨学科研究,受到国内外学术界的良好评价。陈凯先院士的演讲题目是生物医药科技前沿动向和我国发展态势。

9. 樊明武博士, 中国工程院院士, 华中科大

樊明武博士, 中国工程院院士, 华中科大

“Current Status and Development of Proton Therapy Equipment”

质子治疗装备的现状与发展

Dr. Fan is an expert in the field of cyclotron and magnet theory and engineering. He worked in research institutes in the USA, the UK and France, focusing on the research of particle accelerators and electro-physical equipment. He made important contributions to the cyclotron theory during the development and improvement of the cyclotron projects. Dr. Fan solved the critical technical problems during the development of a 30MeV high-current proton. Fan’s innovation of the accelerator was ranked one of China’s Top Ten Scientific and Technological Events in 1996. It started a new era for China and brought China’s ability in developing cyclotrons to a new level. Dr. Fan has authored over 60 publications and two books, and has received two National Science and Technology Awards and nine provincial- and ministerial-level awards. Dr. Fan was the president of the Huazhong Science and Technology University.

樊明武院士, 回旋加速器专家、磁铁理论与工程专家。在磁铁理论与工程领域,基于有限元方法开发了通用二维电磁场计算软件包DE2D,三维磁场计算软件包DE3D。在积分方程法中合理处理奇点和开域,提高了计算精度,解决了大量科研设备及工程难题。发展了回旋加速器理论和主体技术,研制30MeV强流质子回旋加速器,解决了关键设备技术问题,达到当时国际先进水平,磁场计算结果有偿转让国外。该加速器被评选为1996年全国十大科技事件之一,这一事件结束了我国不能用加速器批量生产中短寿命放射性同位素的局面,标志我国回旋加速器的研制能力达到一个新水平。目前,致力于应用型粒子加速器研究、核技术应用及太赫兹波等国际前沿课题的跟踪研究,推进湖北核电和核技术产业发展。获国家级科技进步奖2次,省部级11次,发表论文80余篇,专著4本,1999年当选中国工程院院士。樊明武院士的演讲题目是质子治疗装备的现状与发展。

充满活力热点的主题论坛包括:

1 人工智能在生物医药工业界和健康领域的应用

2 中美双报:捷径还是陷阱?

3 CBA 24年创新创业史

4 免疫肿瘤和现代生物医学技术发展趋势

5 精准医学

6 药物研发和临床实践的全球化及各个相关参与方法

7先进疗法的最新进展和应用

8 产业和资本, 生物医药初创公司孵化器, 中美生物医药商务法规和知识产权论坛

9 创业路演大赛